The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

导语： 在阿尔茨海默病治疗遭遇瓶颈的当下，一款已上市的带状疱疹疫苗正引发科学界的新期待。英国制药巨头葛兰素史克（GSK）宣布与英国痴呆研究所（UK DRI）合作，利用 NHS 接种政策调整形成的 “自然实验”，研究其明星疫苗 Shingrix ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

The British drugmaker is using the health data of some 1.4 million people, some of whom received its Shingrix shot and some ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

Customers concerned about privacy attempted to delete their data but struggled to receive deletion confirmation, The Wall Street Journal reported. In other news: the FDA approves a lab-grown blood ...

GSK has announced a partnership with the UK Dementia Research Institute and Health Data Research UK to explore a potential ...